Status:
COMPLETED
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Lead Sponsor:
Neurana Pharmaceuticals, Inc.
Conditions:
Back Muscle Spasm
Back Pain
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
This is a double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered in subjects with pain due to acute back muscl...
Eligibility Criteria
Inclusion
- Ambulatory
- Current acute back pain due to acute muscle spasm starting within 7 days prior to study entry (Day 1) and at least 8 weeks following resolution of the last episode of acute back pain.
- Willingness to discontinue all previous or ongoing treatment of pain or muscle spasm on study entry at Day 1 through the end of treatment including medication, acupuncture, chiropractic adjustment, massage, transcutaneous electrical nerve stimulation \[TENS\], or physiotherapy.
- Pain must be localized from the neck (C-3 or lower) to the inferior gluteal folds and spasm assessed during the Screening physical examination.
- Body mass index range between 18 and 35 kg/m², inclusive.
Exclusion
- Presence of acute or chronic back pain for the previous 8 days or longer, where back pain is present on more days than not.
- Presence of neurogenic pain in the back, neck, upper or lower extremities, including pain from (or suspected from) nerve root compression or injury (radicular pain or "pinched nerve") or neuropathic pain. Evidence of these types of exclusionary pain includes radiation of pain that radiates beyond the back, chronic pain, and pain associated with abnormal sensation or loss of sensation in the back or extremities.
- Presence of pain anywhere other than the target back pain that is bothersome, interferes with activity, or for which pain relief is taken.
- History of any neck, back, or pelvic surgery.
- History within the previous 3 years of: spinal fracture or spinal infection; inflammatory arthritis; degenerative spine disease; or any other back or spine condition that may reasonably contribute to current back pain.
- Subjects who test positive for alcohol by breathalyzer test or have a positive urine drug screen for drugs of abuse (e.g. amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, oxycodone, opiates), including cannabis even where legal, at Screening.
Key Trial Info
Start Date :
December 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2022
Estimated Enrollment :
1004 Patients enrolled
Trial Details
Trial ID
NCT04671082
Start Date
December 15 2020
End Date
March 21 2022
Last Update
March 22 2022
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Institute of Arizona, LLC
Surprise, Arizona, United States, 85374
2
Applied Research Center of Arkansas
Little Rock, Arkansas, United States, 72212
3
Alliance Research Institute
Canoga Park, California, United States, 91304
4
Long Beach Clinical Trials Services, Inc
Long Beach, California, United States, 90806